In the Specification

Please amend the specification as follows:

Please amend the paragraph beginning at page 7, line 6 as follows:

Figure 6A. Improved Inhibition of Human Colon Cancer by RGD-modified Endostatin. Human colon carcinoma cell line, LS174T was injected s.c. into female athymic mice (10^6 cells/mouse). After tumor establishment (3 days) mice were randomized and treated with endostatin, RGD-endostatin and endostatin-RGD (s.c. about 2 cm away from tumor sites) at a dose of 20 mg/kg/day. Treatment was continued for 14 days. ▲ □ Endostatin; ● RGD-Endostatin; △ ▲, Endostatin-RGD. Mean tumor volume of control (LS174T) and treated groups are shown. Statistical significance was determined by Repeated measurement analysis of variance. The error bars indicate SE.

Please amend the paragraph beginning at page 7, line 15 as follows:

Figure 6B. Improved Inhibition of Human Ovarian Cancer by RGD-modified Endostatin. Human ovarian carcinoma cell line, MA148 (2 x 10^6 cells) was injected s.c. into female athymic mice. After tumor establishment (7 days), mice were randomized and treated with endostatin, RGD-endostatin and endostatin-RGD (s.c. about 2 cm away from tumor sites) at a dose of 20 mg/kg/day. Treatment was continued for 14 days. ▲ □ Endostatin; ● RGD-Endostatin; Δ, Endostatin-RGD. Mean fractional tumor volume (MA148) of control and treated groups are shown. Statistical significance was determined by Repeated measurement analysis of variance. The error bars indicate SE.